Corcept Sinks After Federal Court Rules for Teva in Patent Case

Corcept Therapeutics is down 38% in postmarket trading after a US court ruled in Teva’s favor in a patent infringement case related to the generic drugmaker’s plan to sell a copycat version of Corcept’s Korlym (mifepristone).

• Court finds that Corcept, the plaintiff, hasn’t met its burden of proving induced infringement, according to a ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey

--With assistance from Jeran Wittenstein.

To contact the reporter on this story:
Jeremy R. Cooke in Mount Pleasant, SC at jcooke8@bloomberg.net

To contact the editor responsible for this story: ...